# Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder

Submission date	Recruitment status Recruiting	[X] Prospectively registered		
09/12/2022		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
04/01/2023	Ongoing	Results		
Last Edited	<b>Condition category</b> Mental and Behavioural Disorders	Individual participant data		
15/07/2025		[X] Record updated in last year		

# Plain English summary of protocol

Background and study aims

Generalised anxiety disorder (GAD), characterised by a tendency to worry, is the most common anxiety disorder in older people. Medication and talking therapy are usually offered as forms of treatment, but many do not find them helpful. Guidance on how to help older people manage GAD when it does not respond to such treatments is lacking. In a previous study (the FACTOID study), we developed and tailored a talking therapy intervention to the psychological, physical and cognitive needs of older people with treatment-resistant GAD (TR GAD). This was based on Acceptance and Commitment Therapy (ACT); a form of talking therapy that helps people learn how best to live with distressing thoughts, feelings and sensations, while still doing things that really matter to them. This showed that tailored ACT was acceptable to older people with TR-GAD and it may help improve anxiety, depression and coping. The aim of CONTACT-GAD is to find out whether tailored ACT is helpful for older people with TR-GAD and whether it represents value for money in a larger clinical trial.

# Who can participate?

People aged 60 years and over with TR-GAD that has failed to respond to a previous drug and/or talking treatments or those with TR-GAD who did not want to start or continue these treatments previously and still have symptoms of GAD

#### What does the study involve?

Participants will be allocated at random to either have tailored ACT plus usual care (intervention group) or usual care alone (control group). We will test whether ACT plus usual care leads to a greater reduction in anxiety than usual care alone at 6 months. We will follow people up at 12 months to see if any effects are maintained. We will also look at ACT's value for money, quality of life, depression, adverse effects, satisfaction with ACT and usual care, adherence and behaviour change.

What are the possible benefits and risks of participating?

The main possible benefit is that participants may receive a new type of psychological therapy that has been shown to benefit people with other mood disorders such as depression. The main

possible risk is that participants may experience distress when discussing their current situation in assessments and therapy sessions, or participants' mood may worsen after receiving ACT. Participants remain under the care of their clinical team during the study and will be monitored and referred for further support if necessary.

Where is the study run from? University College London (UK)

When is the study starting and how long is it expected to run for? August 2022 until July 2026

Who is funding the study?

- 1. National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) programme (UK)
- 2. National Health Medical Research Centre National Institute for Health and Care Research (NHMRC-NIHR) Collaborative Research Grant Scheme (Australia)

Who is the main contact?

Prof. Rebecca Gould (r.gould@ucl.ac.uk) (UK)

# Contact information

### Type(s)

Principal investigator

#### Contact name

Prof Rebecca Gould

#### **ORCID ID**

https://orcid.org/0000-0001-9283-1626

#### Contact details

Division of Psychiatry
University College London
Wing B
6th floor Maple House
149 Tottenham Court Rd
London
United Kingdom
W1T 7NF
+44 (0)20 7679 9225
r.gould@ucl.ac.uk

#### Type(s)

Scientific

#### Contact name

Miss Tia Callaghan

#### **ORCID ID**

https://orcid.org/0000-0003-3255-2849

#### Contact details

Clinical Trials Research Unit ScHARR The University of Sheffield 30 Regent Court Sheffield United Kingdom S1 4DA +44 (0)114 222 4397 t.callaghan@sheffield.ac.uk

# Additional identifiers

# Clinical Trials Information System (CTIS)

Nil known

# Integrated Research Application System (IRAS)

320523

# ClinicalTrials.gov (NCT)

Nil known

#### Protocol serial number

CPMS 54812, IRAS 320523

# Study information

#### Scientific Title

A randomised CONtrolled trial of Tailored Acceptance and Commitment Therapy for older people with treatment-resistant generalised anxiety disorder (CONTACT-GAD)

#### Acronym

**CONTACT-GAD** 

# Study objectives

Tailored acceptance and commitment therapy plus usual care will be more clinically and costeffective at reducing anxiety in older people with treatment-resistant generalised anxiety disorder in comparison to usual care alone.

# Ethics approval required

Old ethics approval format

# Ethics approval(s)

Approved 20/12/2022, West of Scotland REC 5 (West of Scotland Research Ethics Service, Ward 11, Dykebar Hospital, Grahamston Road, Paisley, PA2 7DE, Scotland; +44 (0)141 314 0213; WoSREC5@ggc.scot.nhs.uk), ref: none provided

# Study design

Randomized controlled study

## Primary study design

Interventional

# Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Treatment-resistant generalised anxiety disorder (TR-GAD)

#### Interventions

Treatment allocation:

Participants will be randomly allocated 1:1 to either the intervention group (Acceptance and Commitment Therapy [ACT] plus usual care) or the control group (usual care alone). Participants will not be blinded to allocation.

## ACT plus usual care (intervention group):

Participants will be offered up to 14, 1:1 ACT sessions, with each session lasting up to 1 hour, over 6 months, plus a booster session at approximately 3-months post-intervention. There will be a phased ending to the sessions, such that they will be approximately weekly for the first 12 sessions and then approximately fortnightly thereafter, as some older people with generalised anxiety disorder (GAD) can experience difficulties when therapy ends abruptly. Sessions will be delivered in person in the outpatient clinic, GP surgery or participant's home, or via video call or telephone call (where videoconference facilities are not available), depending on participant preference, therapist availability and service restrictions. Therapists who will deliver ACT will be Band 7 or Band 8 clinical psychologists, counselling psychologists, psychotherapists or cognitive behavioural therapy (CBT) therapists who are based in primary or secondary care services, with ≥ 1 year experience of delivering psychotherapy interventions. Ideally, two or more therapists from each recruiting site will be identified, though this will vary across sites depending on therapist availability. All therapists will receive training in ACT and in the delivery of the intervention to older people with treatment-resistant (TR)-GAD. All therapists will attend a 4-day experiential ACT training workshop via video call, delivered by trained members of the research team with a minimum of five years of experience in delivering ACT, as well as experience in training therapists to deliver ACT in clinical trials. Training will be conducted via video call in order to accommodate therapists being located in geographically diverse regions across the UK. Participants in this group will receive usual care in addition to ACT, with the exception of formal psychological therapies such as CBT since this may lead to conflicts in therapeutic approaches and goals.

# Usual care (control group):

Participants in this group will receive usual care, as outlined in NICE clinical guideline 113 for GAD.

## Supervision of therapists delivering ACT:

Therapists will be invited to attend group supervision and consultation via video call on a fortnightly basis, though sessions will be provided weekly to make them as accessible as possible. Group supervision and consultation will be provided by trained members of the research team with a minimum of five years of experience in delivering ACT, as well as experience in supervising ACT, including within a clinical trial. Anonymised supervision notes will be recorded in each session and made available to both supervisors and therapists, and supervisors will observe some of each other's sessions to ensure that a consistent approach is used with therapists. In addition to group supervision and consultation via video call, therapists

will be able to receive support through a secure, supervisor-moderated online forum. Therapists will be able to discuss anonymised issues arising in intervention delivery with supervisors and other therapists. The flexibility of this approach means that therapists will have the opportunity to receive supervisor and peer support between fortnightly group supervision and consultation sessions.

### **Intervention Type**

**Behavioural** 

### Primary outcome(s)

Generalised anxiety disorder measured using the Generalised Anxiety Disorder Assessment (GAD-7) at baseline (0 months), 6-months post-randomisation (the primary endpoint), and 12 months post-randomisation

#### Key secondary outcome(s))

Current secondary outcome measures as of 05/05/2023:

All secondary outcome measures are measured at baseline (0 months), 6-months post-randomisation, and 12 months post-randomisation, with three exceptions. The Client Satisfaction Questionnaire-8 will only be collected at the 6-month follow-up. Adverse events will be collected at 6- and 12-month follow-ups. Data on session attendance for those in the ACT arm will be collected after each session. Secondary outcome measures are as follows:

- 1. Quality of life measured using the McGill Quality of Life Questionnaire-Revised
- 2. Depression measured using the Geriatric Depression Scale-15
- 3. Psychological flexibility measured using the Comprehensive Assessment of ACT processes (CompACT)
- 4. Health and social care resource use measured using a modified version of the Client Service Receipt Inventory
- 5. Health-related quality of life measured using the EQ-5D-5L plus EQ-Visual Analogue Scale
- 6. Capability-adjusted life years measured using the ICECAP-O
- 7. Adverse events
- 8. Satisfaction with ACT and/or usual care measured using the Client Satisfaction Questionnaire-8
- 9. Personally meaningful behaviour change measured using the Goal-Based Outcomes tool
- 10. Cognitive and leisure activities measured using the Cognitive & Leisure Activity Scale
- 11. Adherence (i.e., session attendance for those in the ACT arm)

#### Previous secondary outcome measures:

All secondary outcome measures are measured at baseline (0 months), 6-months post-randomisation, and 12 months post-randomisation, with three exceptions. The Client Satisfaction Questionnaire-8 will only be collected at the 6-month follow-up. Adverse events will be collected at 6- and 12-month follow-ups. Data on session attendance for those in the ACT arm will be collected after each session. Secondary outcome measures are as follows:

- 1. Quality of life measured using the McGill Quality of Life Questionnaire-Revised
- 2. Depression measured using the Geriatric Depression Scale-15
- 3. Psychological flexibility measured using the Comprehensive Assessment of ACT processes (CompACT)
- 4. Health and social care resource use measured using a modified version of the Client Service Receipt Inventory
- 5. Health-related quality of life measured using the EQ-5D-5L plus EQ-Visual Analogue Scale
- 6. Capability-adjusted life years measured using the ICECAP-O
- 7. Adverse events
- 8. Satisfaction with ACT and/or usual care measured using the Client Satisfaction Questionnaire-8

9. Personally meaningful behaviour change measured using the Goal-Based Outcomes tool 10. Adherence (i.e., session attendance for those in the ACT arm)

# Completion date

31/07/2026

# **Eligibility**

#### Key inclusion criteria

For older people with a treatment-resistant generalised anxiety disorder (TR-GAD):

- 1. People aged 60 years and over
- 2. Diagnosis of GAD using the Mini-International Neuropsychiatric Interview
- 3. GAD that is 'treatment resistant', defined as GAD that has failed to respond adequately to pharmacotherapy and/or psychotherapy treatment, as described in step 3 of the UK's stepped care model for GAD. GAD that has failed to respond adequately will be defined as continued symptoms of GAD that are still causing difficulties. Those who have been offered pharmacotherapy and/or psychotherapy treatment and did not want to start it or continue it and are still symptomatic will also be included in this definition. When determining whether GAD has failed to respond adequately to treatment, if a person has remitted and then relapsed in relation to GAD then any treatment received prior to remission will not be considered when deciding whether they meet the criteria for TR-GAD
- 4. Living in the community (i.e. those living in domestic residences or assisted living facilities, but not care homes)

The Mini-International Neuropsychiatric Interview has been modified for the purpose of this trial, with questions surrounding suicidality removed. The expression of suicidal ideation with active suicidal behaviours/plans and active intent is instead assessed via the Geriatric Suicide Ideation Scale, as detailed in the principal exclusion criteria.

For study therapists completing the qualitative satisfaction questionnaire:

- 1. Aged 18 years and over
- 2. Therapists involved in intervention delivery within the CONTACT-GAD trial

#### Participant type(s)

Patient

## Healthy volunteers allowed

No

#### Age group

Adult

#### Lower age limit

60 years

#### Sex

All

### Key exclusion criteria

Current participant exclusion criteria as of 05/05/2023:

For older people with TR-GAD:

- 1. Judged to lack the capacity to provide fully informed written consent to participate in the trial
- 2. A diagnosis of dementia or intellectual disability using standard diagnostic guidelines, or clinically judged to have moderate or severe cognitive impairment (e.g. due to probable dementia, traumatic brain injury, stroke, etc)
- 3. A diagnosis of an imminently life-limiting illness where they would not be expected to survive for the duration of the study
- 4. Expressing suicidal ideation with active suicidal behaviours/plans and active intent, as assessed using the Columbia-Suicide Severity Rating Scale Screener, for whom an inpatient admission would be more appropriate
- 5. Currently receiving a course of formal psychological therapy delivered by a formally trained psychologist or psychotherapist (e.g. cognitive behavioural therapy, psychodynamic psychotherapy, systemic therapy, counselling, etc), or those who are unwilling to refrain from engaging in such formal psychological therapy should they be randomly allocated to the ACT arm 6. Self-report having received ACT in the FACTOID feasibility study
- 7. Having already been randomised in the CONTACT-GAD trial or living with another person who has already been randomised in the CONTACT-GAD trial
- 8. Taking part in clinical trials of other interventions for GAD

Previous participant exclusion criteria:

For older people with TR-GAD:

- 1. Judged to lack the capacity to provide fully informed written consent to participate in the trial
- 2. A diagnosis of dementia or intellectual disability using standard diagnostic guidelines, or clinically judged to have moderate or severe cognitive impairment (e.g. due to probable dementia, traumatic brain injury, stroke, etc)
- 3. A diagnosis of an imminently life-limiting illness where they would not be expected to survive for the duration of the study
- 4. Expressing suicidal ideation with active suicidal behaviours/plans and active intent, as assessed using the Geriatric Suicide Ideation Scale, for whom an inpatient admission would be more appropriate
- 5. Currently receiving a course of formal psychological therapy delivered by a formally trained psychologist or psychotherapist (e.g. cognitive behavioural therapy, psychodynamic psychotherapy, systemic therapy, counselling, etc), or those who are unwilling to refrain from engaging in such formal psychological therapy should they be randomly allocated to the ACT arm 6. Self-report having received ACT in the FACTOID feasibility study
- 7. Having already been randomised in the CONTACT-GAD trial or living with another person who has already been randomised in the CONTACT-GAD trial
- 8. Taking part in clinical trials of other interventions for GAD

Date of first enrolment 24/05/2023

Date of final enrolment 31/01/2026

# Locations

**Countries of recruitment**United Kingdom

England

Wales

Australia

# Study participating centre Humber Teaching NHS Foundation Trust

Trust Hq, Willerby Hill Beverley Road Willerby Hull United Kingdom HU10 6ED

# Study participating centre Oxleas NHS Foundation Trust

Pinewood House Pinewood PLACE Dartford United Kingdom DA2 7WG

# Study participating centre Sheffield Health & Social Care NHS Foundation Trust

Centre Court Atlas Way Sheffield United Kingdom S4 7QQ

# Study participating centre Oxford Health NHS Foundation Trust

Warneford Hospital Warneford Lane Headington Oxford United Kingdom OX3 7JX

# Study participating centre

# Lincolnshire Partnership NHS Foundation Trust

St George's Long Leys Road Lincoln United Kingdom LN1 1FS

# Study participating centre Midlands Partnership NHS Foundation Trust

Trust Headquarters St Georges Hospital Corporation Street Stafford United Kingdom ST16 3SR

# Study participating centre Cardiff and Vale UHB United Kingdom CF14 4XW

# Study participating centre Cwm Taf Morgannwg Uhb

Cds, Dental Department Treharris Health Centre Treharris United Kingdom CF46 5HE

# Study participating centre Derbyshire Healthcare NHS Foundation Trust

Trust Headquarters Kingsway Hospital Kingsway Derby United Kingdom DE22 3LZ

# Study participating centre Norfolk and Suffolk NHS Foundation Trust Hellesdon Hospital

Drayton High Road Norwich United Kingdom NR6 5BE

# Study participating centre Tees, Esk and Wear Valleys NHS Foundation Trust

Trust Headquarters West Park Hospital Edward Pease Way Darlington United Kingdom DL2 2TS

# Study participating centre Barnet, Enfield and Haringey Mental Health NHS Trust

Trust Headquarters Block B2 St Ann's Hospital St Ann's Road London United Kingdom N15 3TH

# Study participating centre Herefordshire and Worcestershire Health and Care NHS Trust

Unit 2 Kings Court Charles Hastings Way Worcester United Kingdom WR5 1JR

# Study participating centre

Greater Manchester Mental Health NHS Foundation Trust

Prestwich Hospital Bury New Road Prestwich Manchester United Kingdom M25 3BL

# Study participating centre

#### **East London NHS Foundation Trust**

Robert Dolan House 9 Alie Street London United Kingdom E1 8DE

# Study participating centre Whittington Health NHS Trust

The Whittington Hospital Magdala Avenue London United Kingdom N19 5NF

# Study participating centre Essex Partnership University NHS Foundation Trust

The Lodge Lodge Approach Runwell Wickford United Kingdom SS11 7XX

# Study participating centre North East London NHS Foundation Trust

West Wing C E M E Centre Marsh Way Rainham United Kingdom RM13 8GQ

# Study participating centre Surrey and Borders Partnership NHS Foundation Trust

18 Mole Business Park Randalls Road Leatherhead United Kingdom KT22 7AD

# Study participating centre Macquarie University

Balaclava Rd Macquarie Park Sydney Australia NSW 2113

# Study participating centre West London NHS Trust

1 Armstrong Way Southall London United Kingdom UB2 4SD

# Sponsor information

#### Organisation

Camden and Islington NHS Foundation Trust

#### **ROR**

https://ror.org/03ekq2173

# Funder(s)

# Funder type

Government

#### **Funder Name**

National Institute for Health and Care Research

## Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

### **Funding Body Type**

Government organisation

# Funding Body Subtype

National government

### Location

**United Kingdom** 

### **Funder Name**

National Health Medical Research Centre - National Institute for Health and Care Research (NHMRC-NIHR) Collaborative Research Grant Scheme (Australia)

# **Results and Publications**

# Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

# IPD sharing plan summary

Data sharing statement to be made available at a later date

# **Study outputs**

Output type	Details	Date created	Date added Peer review	ed? Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025 No	Yes
Study website	Study website	11/11/2025	11/11/2025 No	Yes